Incyclix Bio, LLC is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 600 Park Office Dr,
- Industry
- Biotechnology
- Website
- http://www.incyclixbio.com
- Keywords
- Durham.
- HQ
- Durham, North Carolina
Incyclix Bio Questions
Incyclix Bio's website is http://www.incyclixbio.com
Incyclix Bio's LinkedIn profile is https://www.linkedin.com/company/incyclix-bio-llc
Incyclix Bio has
10 employees.
View email and phone details for 10
employees at Incyclix Bio.
Incyclix Bio's industry is
Biotechnology
Incyclix Bio's top competitors are
Madera Therapeutics,
Biovaxys Technology Corp.,
Precision Biosciences, Inc.,
Tavros Therapeutics,
Grid Therapeutics,
Ribometrix Inc.,
Evecxia Therapeutics, Inc.,
Pinetree Therapeutics Inc,
Chordoma Foundation,
Omideon Limited.
Incyclix Bio's categories are Biotechnology
Incyclix Bio's founding year is 2020
